Read by QxMD icon Read

transarterial chemoembolisation

S S Kim, T W Kang, K D Song, S K Cho, M W Lee, H Rhim, D H Sinn, S-H Jung
AIM: To evaluate the efficacy of radiofrequency ablation (RFA) and transarterial chemoembolisation (TACE) as a first-line treatment for isolated intrahepatic recurrent hepatocellular carcinoma (IIR-HCC) after liver transplantation (LT). MATERIALS AND METHODS: This retrospective study was approved by the institutional review board. Between January 2005 and January 2015, 588 consecutive patients underwent LT for the treatment of HCC. Among them, 27 patients with IIR-HCCs after LT who were treated with RFA (n=6) or TACE (n=21) as a first-line treatment were retrospectively included in this study...
October 11, 2016: Clinical Radiology
F Abdul Rahman, J Naidu, C S Ngiu, Y Yaakob, Z Mohamed, H Othman, R Jarmin, M H Elias, N Abdul Hamid, N Mohd Mokhtar, Ra Raja Ali
BACKGROUND: Hepatocellular carcinoma (HCC) is a common cancer that is frequently diagnosed at an advanced stage. Transarterial chemoembolisation (TACE) is an effective palliative treatment for patients who are not eligible for curative treatment. The two main methods for performing TACE are conventional (c-TACE) or with drug eluting beads (DEB-TACE). We sought to compare survival rates and tumour response between patients undergoing c-TACE and DEB-TACE at our centre. MATERIALS AND METHODS: A retrospective cohort study of patients undergoing either treatment was carried out from January 2009 to December 2014...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
Fabiola Fernández-Gutiérrez, Malgorzata Wolska-Krawczyk, Arno Buecker, J Graeme Houston, Andreas Melzer
This study presents a framework for workflow optimisation of multimodal image-guided procedures (MIGP) based on discrete event simulation (DES). A case of a combined X-Ray and magnetic resonance image-guided transarterial chemoembolisation (TACE) is presented to illustrate the application of this method. We used a ranking and selection optimisation algorithm to measure the performance of a number of proposed alternatives to improve a current scenario. A DES model was implemented with detail data collected from 59 TACE procedures and durations of magnetic resonance imaging (MRI) diagnostic procedures usually performed in a common MRI suite...
August 26, 2016: Minimally Invasive Therapy & Allied Technologies: MITAT
B Bock, D Hasdemir, F Wandrer, T Rodt, M P Manns, K Schulze-Osthoff, H Bantel
BACKGROUND: Hepatocellular carcinoma (HCC) represents an increasing health problem with limited therapeutic options. In patients with intermediate disease stage, transarterial chemoembolisation (TACE) is widely applied. Treatment response is routinely assessed by imaging techniques according to the international response evaluation criteria in solid tumours (RECIST), which consider tumour regression or additionally tumour necrosis (modified RECIST). Evaluation of treatment response, however, by these methods is time- and cost-intensive and usually performed at earliest several months following TACE...
October 2016: Alimentary Pharmacology & Therapeutics
Amélie Anota, Mathieu Boulin, Sandrine Dabakuyo-Yonli, Patrick Hillon, Jean-Pierre Cercueil, Anne Minello, Jean-Louis Jouve, Xavier Paoletti, Laurent Bedenne, Boris Guiu, Franck Bonnetain
OBJECTIVES: The objective of this study was to explore the association between health-related quality of life (HRQoL) and the recommended phase 2 dose in a phase I clinical trial according to the Time to HRQoL deterioration approach (TTD). SETTING: This is a phase I dose-escalation trial of transarterial chemoembolisation (TACE) with idarubicin-loaded beads performed in cirrhotic patients with hepatocellular carcinoma. Patients had to complete the EORTC QLQ-C30 HRQoL questionnaire at baseline and at days 15, 30 and 60 after TACE...
2016: BMJ Open
Asahiro Morishita, Hirohito Yoneyama, Takako Nomura, Teppei Sakamoto, Koji Fujita, Joji Tani, Hisaaki Miyoshi, Reiji Haba, Tsutomu Masaki
We herein present a case of an 87-year-old patient with multiple liver tumors identified on abdominal ultrasound. The assessment performed on admission included physical examination, computed tomography (CT) during hepatic angiography and CT during arterial portography. The examination revealed contrast enhancement of a proportion of the liver tumors (20 mm maximum diameter) during the arterial phase and mild contrast washout of those tumors during the delayed phase. On contrast-enhanced magnetic resonance imaging using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid, certain liver tumors exhibited contrast enhancement during the early phase and contrast washout during the hepatocyte phase in both lobes...
June 2016: Molecular and Clinical Oncology
Olga Golubnitschaja, Kristina Yeghiazaryan, Helena Stricker, Daniela Trog, Hans H Schild, Leonard Berliner
BACKGROUND: Patients with primary and metastatic liver malignancies represent a highly heterogeneous patient pool characterised by some of the shortest life expectancies amongst oncology patients. Investigation and better understanding of liver malignancies is an emerging field which requires high-quality multidisciplinary research and collaboration. METHODS: A study of 158 patients with primary hepatic carcinomas and secondary liver metastases, altogether 15 cancer types of different origin, who underwent selective internal radiation therapy (SIRT) with Yttrium(90) or transarterial chemoembolisation, was undertaken in an effort to detect distinguishing features with respect to activity profiles of both blood matrix metalloproteinase (MMP-2 and MMP-9)...
2016: BMC Cancer
Masatoshi Kudo, Riccardo Lencioni, Jorge A Marrero, Alan P Venook, Jean-Pierre Bronowicki, Xiao-Ping Chen, Lucy Dagher, Junji Furuse, Jean-Francois H Geschwind, Laura Ladrón de Guevara, Christos Papandreou, Arun J Sanyal, Tadatoshi Takayama, Seung Kew Yoon, Keiko Nakajima, Robert Lehr, Stephanie Heldner, Sheng-Long Ye
BACKGROUND & AIMS: Treatment approaches for hepatocellular carcinoma (HCC) vary across countries, but these differences and their potential impact on outcomes have not been comprehensively assessed. Data from the multinational GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) registry evaluated differences in patient characteristics, practice patterns and outcomes in HCC across geographical regions in patients who received sorafenib. METHODS: GIDEON is a non-randomised, observational registry study conducted in 39 countries across five global regions...
August 2016: Liver International: Official Journal of the International Association for the Study of the Liver
B Bodelle, S Isler, J-E Scholtz, C Frellesen, W Luboldt, T J Vogl, M Beeres
AIM: To evaluate the advantage of sinogram-affirmed iterative reconstruction (SIR) compared to filtered back projection (FBP) in upper abdomen computed tomography (CT) after transarterial chemoembolisation (TACE) at different tube currents. MATERIALS AND METHODS: The study was approved by the institutional review board. Written informed consent was obtained from all patients. Post-TACE CT was performed with different tube currents successively varied in four steps (180, 90, 45 and 23 mAs) with 40 patients per group (mean age: 60±12 years, range: 23-85 years, sex: 70 female, 90 male)...
January 2016: Clinical Radiology
Xingshun Qi, Xiaozhong Guo
Sorafenib is the first-line treatment of choice for advanced hepatocellular carcinoma (HCC). However, the benefits of sorafenib in HCC patients with portal vein tumour thrombosis (PVTT) remain uncertain. Until now, a total of eight comparative studies have been identified for this systematic review. Four retrospective studies showed that hepatic arterial infusion chemotherapy, hepatic resection, and three-dimensional conformal radiotherapy might be superior to sorafenib in improving the overall survival. Two ongoing randomised controlled trials (RCTs) will compare the outcomes of transarterial chemoembolisation or radioembolisation with those of sorafenib for the treatment of HCC with PVTT...
2015: Przegla̜d Gastroenterologiczny
Alzhraa Alkhatib, Asmaa Gomaa, Naglaa Allam, Eman Rewisha, Imam Waked
BACKGROUND: Real life management of hepatocellular carcinoma occasionally deviates from guidelines for recommended therapy. AIMS: To evaluate how frequent this deviation happens in our center and assess its impact on outcome. MATERIALS AND METHODS: The treatment of 770 patients (87% males, mean age 57.8 years) was analyzed and the effect of deviation on outcome over 36 months was examined. RESULTS: Of Barcelona Clinic liver cancer stages 0 and A patients, 65...
2015: Asian Pacific Journal of Cancer Prevention: APJCP
Mohamed A S Kohla, Mai I Abu Zeid, Mohamed Al-Warraky, Hossam Taha, Robert G Gish
AIM: To study predictive factors for hepatic decompensation after transarterial chemoembolisation (TACE) for hepatocellular carcinoma (HCC). METHODS: Between November 2009 and August 2010, of 254 patients with HCC who presented to our multidisciplinary HCC clinic for evaluation, 102 (40%) were amenable for TACE. In this prospective study, there were 102 patients with compensated cirrhosis with HCC and Child-Pugh Class A cirrhosis who underwent TACE at the National Liver Institute, Menoufiya University, Egypt...
2015: BMJ Open Gastroenterology
Kerlijne De Groote, Hans Prenen
In patients with metastatic colorectal cancer, the liver is the most common site of metastatic disease. In patients with liver-dominant disease, consideration needs to be given to locoregional treatments such as hepatic arterial infusion chemotherapy, transarterial chemoembolisation and selective internal radiation therapy because hepatic metastases are a major cause of liver failure especially in chemorefractory disease. In this review we provide insights on the published literature for locoregional treatment of liver metastases in metastatic colorectal cancer...
September 15, 2015: World Journal of Gastrointestinal Oncology
Mathieu Boulin, Antonin Schmitt, Elisabeth Delhom, Jean-Pierre Cercueil, Maëva Wendremaire, Diane-Charlotte Imbs, Audrey Fohlen, Fabrizio Panaro, Astrid Herrero, Alban Denys, Boris Guiu
OBJECTIVES: To investigate the relationship between the improved stability of an anticancer drug-lipiodol emulsion and pharmacokinetic (PK) profile for transarterial chemoembolisation (TACE) of hepatocellular carcinoma (HCC). METHODS: The stability of four doxorubicin- or idarubicin-lipiodol emulsions was evaluated over 7 days. PK and clinical data were recorded after TACE with the most stable emulsion in eight unresectable HCC patients, after institutional review board approval...
February 2016: European Radiology
Nai-Jian Ge, Zhi-Yong Shi, Xiao-He Yu, Xiao-Jun Huang, You-Sheng Wu, Yuan-Yuan Chen, Jin Zhang, Ye-Fa Yang
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide. Transarterial chemoembolisation (TACE) is the standardized therapy for intermediate stage HCC. However, the prognosis for HCC patients treated by TACE greatly varies. Thus, there is a critical need for finding biomarkers to predict the prognosis of HCC patients. The amino acid transporter-2 (ASCT2) is involved in tumorigenesis and progression of many malignancies. This study aimed to evaluate the predictive role of two single nuclear polymorphisms (SNPs, rs3826793 and rs2070246) in the ASCT2 gene in HCC patients treated by TACE...
2015: Asian Pacific Journal of Cancer Prevention: APJCP
Abhihav Vasudevan, Manfred Spanger, John S Lubel
No abstract text is available yet for this article.
March 2015: Journal of Clinical and Experimental Hepatology
Mona Fouad, Omar Abdel-Rahman
BACKGROUND: Hepatocellular carcinoma (HCC) is the most frequently occurring liver neoplasm and the fifth most common cancer worldwide. Intermediate-stage HCC is a distinct disease entity that is traditionally treated with transarterial chemoembolisation (TACE). However, the risk of viral reactivation and subsequent hepatic decompensation is considerable. Therefore, in this systematic review, we explore the evidence surrounding the benefits of using TACE/antiviral combination in this subset of HCC...
June 2015: Arab Journal of Gastroenterology: the Official Publication of the Pan-Arab Association of Gastroenterology
H J Khoury, W J Garzon, G Andrade, N Lunelli, R Kramer, V S M de Barros, A Huda
The purpose of this study was to evaluate patient and medical staff absorbed doses received from transarterial chemoembolisation of hepatocellular carcinoma, which is the most common primary liver tumour worldwide. The study was performed in three hospitals in Recife, capital of the state of Pernambuco, located in the Brazilian Northeastern region. Two are public hospitals (A and B), and one is private (C). For each procedure, the number of images, irradiation parameters (kV, mA and fluoroscopy time), the air kerma-area product (PKA) and the cumulative air kerma (Ka,r) at the reference point were registered...
July 2015: Radiation Protection Dosimetry
T V Prasad, K S Madhusudhan, Deep N Srivastava, Nihar R Dash, Arun K Gupta
Solid pseudo-papillary epithelial neoplasm (SPEN) is a rare epithelial tumor of pancreas with a low malignant potential occurs most commonly in young females. We report a case of 40 years old woman presented with extensive liver metastasis from SPEN of pancreatic body for which she was operated four years ago. Due to the extensive nature of metastatic disease she was offered Transarterial chemoembolisation (TACE) using gemcitabine as chemotherapeutic agent. Short term follow up after a month of TACE with multiphase computed tomography showed > 90% resolution in the viable tumor with significant clinical improvement...
March 28, 2015: World Journal of Radiology
M M Kirstein, N Schweitzer, S Schmidt, A Klöpper, K I Ringe, U Lehmann, M P Manns, H Wedemeyer, A Vogel
The multi-kinase inhibitor sorafenib still remains the only approved agent for advanced HCC. Its benefits typically involve disease stabilisation, whereas an induction of response is rare. We report a series of five cases with extraordinary response to sorafenib. For two patients complete response to sorafenib was reported with a recurrence-free survival of 51 and 21 months. In another HCC patient pretreated with transarterial chemoembolisation (TACE) sorafenib treatment resulted in a complete response with no evidence of disease 18 months after first diagnosis...
December 2014: Acta Gastro-enterologica Belgica
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"